Literature DB >> 29884853

Daratumumab at the frontiers of post-transplant refractory T-acute lymphoblastic leukemia-a worthwhile strategy?

Avinash Bonda1, Sachin Punatar1, Anant Gokarn1, Aniket Mohite1, Kartthik Shanmugam1, Lingaraj Nayak1, Mounika Bopanna1, Badira Cheriyalinkal Parambil1, Navin Khattry2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29884853     DOI： 10.1038/s41409-018-0222-5

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  11 in total

1.  CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy.

Authors:  Sarah Leong; Sarah Inglott; Foteini Papaleonidopoulou; Karen Orfinada; Philip Ancliff; Jack Bartram; Ben Carpenter; Adele K Fielding; Sara Ghorashian; Victoria Grandage; Rajeev Gupta; Rachael Hough; Asim Khwaja; Vesna Pavasovic; Anupama Rao; Sujith Samarasinghe; Ajay Vora; Marc R Mansour; David O'Connor
Journal:  Blood Adv       Date:  2020-10-13

2.  Harnessing immunotherapy for pediatric T-cell malignancies.

Authors:  Caroline Diorio; David T Teachey
Journal:  Expert Rev Clin Immunol       Date:  2020-02-27       Impact factor: 5.124

3.  Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy.

Authors:  Prashant Ramesh Tembhare; Harshini Sriram; Twinkle Khanka; Gaurav Chatterjee; Devasis Panda; Sitaram Ghogale; Yajamanam Badrinath; Nilesh Deshpande; Nikhil V Patkar; Gaurav Narula; Bhausaheb Bagal; Hasmukh Jain; Manju Sengar; Navin Khattry; Shripad Banavali; Sumeet Gujral; Papagudi G Subramanian
Journal:  J Immunother Cancer       Date:  2020-05       Impact factor: 13.751

Review 4.  Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia.

Authors:  Veronica A Guerra; Elias J Jabbour; Farhad Ravandi; Hagop Kantarjian; Nicholas J Short
Journal:  Ther Adv Hematol       Date:  2019-05-19

5.  Approach to the Adult Acute Lymphoblastic Leukemia Patient.

Authors:  Valentina Sas; Vlad Moisoiu; Patric Teodorescu; Sebastian Tranca; Laura Pop; Sabina Iluta; Sergiu Pasca; Cristina Blag; Sorin Man; Andrei Roman; Catalin Constantinescu; Ioana Rus; Mihail Buse; Bogdan Fetica; Mirela Marian; Cristina Selicean; Ioana Berindan-Neagoe; Bobe Petrushev; Horia Bumbea; Alina Tanase; Mihnea Zdrenghea; Shigeo Fuji; Shigehisa Kitano; Ciprian Tomuleasa
Journal:  J Clin Med       Date:  2019-08-06       Impact factor: 4.241

6.  Controversial Flow Cytometry Monitoring of a Relapse Case of Pediatric T Cell Acute Lymphoblastic Leukemia: A Case Report.

Authors:  Delia Codruţa Popa; Andreea Şerbănică; Radu Obrisca; Ionut Şerbănică; Letiţia Radu; Cristina Jercan; Andra Marcu; Ana Bica; Minodora Asan; Mădălina Petran; Mihaela Dragomir; Cerasela Jardan; Valeria Ţică; Anca Gheorghe; Irina Stoian; Daniel Coriu; Anca Coliţă; Andrei Coliţă
Journal:  Front Med (Lausanne)       Date:  2022-03-22

7.  Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript.

Authors:  Sophie Voruz; Sabine Blum; Laurence de Leval; Jacqueline Schoumans; Françoise Solly; Olivier Spertini
Journal:  Biomark Res       Date:  2021-12-20

Review 8.  Early precursor T-cell acute lymphoblastic leukemia: current paradigms and evolving concepts.

Authors:  Omar Castaneda Puglianini; Nikolaos Papadantonakis
Journal:  Ther Adv Hematol       Date:  2020-07-16

9.  Salvage Therapy in Early Relapse of T-Lymphoblastic Leukemia/Lymphoma Using Daratumumab/Nelarabine Combination: Two Consecutive Cases.

Authors:  Ingolf Molle; Irma Petruskevicius; Peter Kamper; Francesco d'Amore
Journal:  Case Rep Hematol       Date:  2022-01-10

10.  Daratumumab: new indications revolving around "off-targets".

Authors:  Yishai Ofran
Journal:  Haematologica       Date:  2021-12-01       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.